We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portable Device Developed for Early-Stage Malaria Detection

By LabMedica International staff writers
Posted on 13 Jun 2018
Over 216 million people were infected with malaria in 2016, and 445,000 individuals died from the disease. More...
The key to solving this health crisis is early-stage diagnosis when malaria therapeutics are most effective.

There are two standard ways of diagnosing malaria, yet both have limitations. The first involves taking a blood sample from a person and looking at it underneath a microscope for red blood cells that have been infected with the malaria parasite. Another method are the rapid diagnostic tests.

Bioengineers at the University of Southern California (Los Angeles, CA, USA) have developed a portable, magneto-optic technology for early stage malaria diagnosis based on the detection of the malaria pigment, hemozoin. The portable optical diagnostics system (PODS) prototype detects a byproduct generated by all species of the malaria parasite, as such; it is a rapid screening for all malaria strains. Because the amount of hemozoin in the blood is directly related to how far the malaria infection has progressed, it is an ideal indicator of infection.

By applying a magnet, it is possible to manipulate and move the hemozoin particles within a test tube around, or move them in and out of the laser beam. In this way, a single sample can be used to perform two measurements, and every diagnosis is personalized. If hemozoin is present, even in minute concentrations, the signals change. On average, it takes between 10 to 15 minutes for the signal to stabilize, and a larger difference between the two measurements indicates that the malaria has progressed farther. The scientists used β-hematin, a hemozoin mimic, and they demonstrated detection limits of less than 0.0081 μg/mL in 500 μL of whole rabbit blood with no additional reagents required. This level corresponds to less than 26 parasites/μL, a full order of magnitude below clinical relevance and comparable to or less than existing technologies.

Andrea Martin Armani, PhD, a professor of Chemical Engineering and Materials Science, and senior author of the study, said, “Malaria primarily impacts low-resource environments where supply chain management is difficult and access to power can be unreliable. Therefore, an effective malaria diagnostic must be independent of these.” The study was published on May 21, 2018, in the journal ACS Sensors.

Related Links:
University of Southern California


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.